<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00296374</url>
  </required_header>
  <id_info>
    <org_study_id>D3569C00007</org_study_id>
    <secondary_id>PLANET 1</secondary_id>
    <nct_id>NCT00296374</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease</brief_title>
  <acronym>PLANET 1</acronym>
  <official_title>Randomised, Double-blind, 52-wk, Parallel-grp, Multicentre, PIIb Study to Evaluate Effects of Rosuvastatin 10mg, Rosuvastatin 40mg and Atorvastatin 80mg on Urinary Protein Excretion in Hypercholesterolaemic Diabetic Patients With Moderate Proteinuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor)
      atorvastatin on urinary protein excretion over 1 year in patients with Type 1 or 2 diabetes
      with moderate proteinuria and hypercholesterolaemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes.</measure>
    <time_frame>Assessed at Week 52, Last observation carried forward (LOCF)</time_frame>
    <description>Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 [LOCF] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary Protein/Creatinine Ratio at Week 26.</measure>
    <time_frame>Assessed at Week 26</time_frame>
    <description>Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine protein/creatinine ratio over baseline urine protein/creatinine ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Albumin/Creatinine Ratio at Week 26</measure>
    <time_frame>Assessed at Week 26</time_frame>
    <description>Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]</measure>
    <time_frame>Assessed at Week 52 LOCF</time_frame>
    <description>Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 [LOCF] urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26</measure>
    <time_frame>Assessed at Baseline and Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in eGFR at Week 52 [LOCF]</measure>
    <time_frame>Assessed at Baseline and Week 52 [LOCF]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Coefficient Urinary Protein/Creatinine Ratio and Total Cholesterol [TC] Indicating the Relationship Between Renal Effects and Lipid Changes</measure>
    <time_frame>52 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52 (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio TC</measure>
    <time_frame>Assessed at 52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Low Density Lipoprotein Cholesterol [LDL-C]</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and High Density Lipoprotein Cholesterol [HDL-C]</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and HDL-C</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Non-high Density Lipoprotein Cholesterol [nonHDL-C]</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Triglyceride [TG]</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TG</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein A-1 [ApoA-1]</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoA-1</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein B [ApoB]</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and TC</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and TC</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C</measure>
    <time_frame>52 weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and TG</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and TG</measure>
    <time_frame>52 weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio</measure>
    <time_frame>52 weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio</measure>
    <time_frame>52 weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio</measure>
    <time_frame>52 weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1</measure>
    <time_frame>52 weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB</measure>
    <time_frame>52 weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio</measure>
    <time_frame>26 weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio</measure>
    <time_frame>52 weeks</time_frame>
    <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">353</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 80 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>10 mg oral dose administered once daily for 52 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>20 mg oral dose administered once daily for 4 weeks followed by 40 mg oral dose administered once daily for 48 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>40 mg oral dose administered once daily for 4 weeks followed by 80 mg oral dose administered once daily for 48 weeks</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hyperlipidemia

          -  urinary protein

          -  diabetes

        Exclusion Criteria:

          -  previous rosuvastatin treatment &lt; 6 months prior to Visit 1

          -  statin intolerance

          -  severe hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca Crestor Medical Science Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Avondale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orchard Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reasearch Site</name>
      <address>
        <city>La Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moron</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quilmes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fortaleza</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goiania</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Recife</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burgas</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gabrovo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Veliko Tarnovo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Courtice</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Blegdamsvej 9</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Farso</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gentofte</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hillerod</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koge</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Annonay</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Besan√ßon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bondy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Corbeil Essonnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Corsept</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Creil Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grenoble Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Chapelle Sur Erdre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quimper</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baja</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Balatonfured</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyor</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hodmeztvasarhely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kecskem√©t</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Keszthely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mosonmagyarovar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sz√©kesfeh√©rv√°r</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tatabanya</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Acireale</city>
        <state>CT</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sottomarnia Di Chioggia</city>
        <state>VE</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Treviglio</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cauntla</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Distrito Federal</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durango</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saltillo</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Luis Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zapopan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baia Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Targu Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.astrazeneca.com/node/emailtriage.aspx</url>
    <description>AstraZeneca Clinical Trial Information - Outside US</description>
  </link>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2006</study_first_submitted>
  <study_first_submitted_qc>February 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2006</study_first_posted>
  <results_first_submitted>March 3, 2010</results_first_submitted>
  <results_first_submitted_qc>November 30, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 30, 2010</results_first_posted>
  <last_update_submitted>August 30, 2011</last_update_submitted>
  <last_update_submitted_qc>August 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperlipidemia</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>353 patients entered the study with Type 1 or 2 diabetes and were receiving current treatment with angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs). The study was conducted at 147 centers in 11 countries.</recruitment_details>
      <pre_assignment_details>Patients requiring an adjustment of the ACE inhibitor and/or ARBs after Visit 1 were excluded. All 353 patients were randomized and 276 patients completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rosuvastatin 10mg</title>
        </group>
        <group group_id="P2">
          <title>Rosuvastatin 40mg</title>
        </group>
        <group group_id="P3">
          <title>Atorvastatin 80mg</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="124"/>
                <participants group_id="P3" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect enrollment</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocated to another state</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Stopped drug before end of study visit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Nephrologist introduced ACE</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rosuvastatin 10mg</title>
        </group>
        <group group_id="B2">
          <title>Rosuvastatin 40mg</title>
        </group>
        <group group_id="B3">
          <title>Atorvastatin 80mg</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="118"/>
            <count group_id="B2" value="124"/>
            <count group_id="B3" value="111"/>
            <count group_id="B4" value="353"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated glomerular filtration rate [eGFR]</title>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.759" spread="24.1080"/>
                    <measurement group_id="B2" value="72.644" spread="25.8018"/>
                    <measurement group_id="B3" value="72.149" spread="24.8721"/>
                    <measurement group_id="B4" value="71.210" spread="24.9455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine albumin/creatinine ratio</title>
          <units>mg/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1036.478" spread="730.6185"/>
                    <measurement group_id="B2" value="1079.802" spread="725.7039"/>
                    <measurement group_id="B3" value="1143.198" spread="779.5282"/>
                    <measurement group_id="B4" value="1085.435" spread="743.5360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine protein/creatinine ratio</title>
          <units>mg/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1392.26" spread="888.3215"/>
                    <measurement group_id="B2" value="1493.574" spread="996.0972"/>
                    <measurement group_id="B3" value="1517.858" spread="969.7020"/>
                    <measurement group_id="B4" value="1467.843" spread="952.0380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes.</title>
        <description>Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 [LOCF] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.</description>
        <time_frame>Assessed at Week 52, Last observation carried forward (LOCF)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 10mg</title>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin 40mg</title>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 80mg</title>
          </group>
        </group_list>
        <measure>
          <title>Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes.</title>
          <description>Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 [LOCF] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.</description>
          <units>mg/g</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.016" lower_limit="0.858" upper_limit="1.209"/>
                    <measurement group_id="O2" value="0.955" lower_limit="0.869" upper_limit="1.185"/>
                    <measurement group_id="O3" value="0.874" lower_limit="0.733" upper_limit="0.975"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Protein/Creatinine Ratio at Week 26.</title>
        <description>Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine protein/creatinine ratio over baseline urine protein/creatinine ratio.</description>
        <time_frame>Assessed at Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 10mg</title>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin 40mg</title>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 80mg</title>
          </group>
        </group_list>
        <measure>
          <title>Urinary Protein/Creatinine Ratio at Week 26.</title>
          <description>Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine protein/creatinine ratio over baseline urine protein/creatinine ratio.</description>
          <units>mg/g</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.007" lower_limit="0.895" upper_limit="1.133"/>
                    <measurement group_id="O2" value="0.994" lower_limit="0.881" upper_limit="1.121"/>
                    <measurement group_id="O3" value="0.876" lower_limit="0.784" upper_limit="0.979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Albumin/Creatinine Ratio at Week 26</title>
        <description>Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.</description>
        <time_frame>Assessed at Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 10mg</title>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin 40mg</title>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 80mg</title>
          </group>
        </group_list>
        <measure>
          <title>Urinary Albumin/Creatinine Ratio at Week 26</title>
          <description>Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.</description>
          <units>mg/g</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.927" lower_limit="0.792" upper_limit="1.085"/>
                    <measurement group_id="O2" value="0.913" lower_limit="0.788" upper_limit="1.058"/>
                    <measurement group_id="O3" value="0.831" lower_limit="0.726" upper_limit="0.951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]</title>
        <description>Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 [LOCF] urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.</description>
        <time_frame>Assessed at Week 52 LOCF</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 10mg</title>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin 40mg</title>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 80mg</title>
          </group>
        </group_list>
        <measure>
          <title>Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]</title>
          <description>Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 [LOCF] urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.</description>
          <units>mg/g</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.016" lower_limit="0.856" upper_limit="1.206"/>
                    <measurement group_id="O2" value="0.836" lower_limit="0.704" upper_limit="0.993"/>
                    <measurement group_id="O3" value="0.823" lower_limit="0.709" upper_limit="0.954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26</title>
        <time_frame>Assessed at Baseline and Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 10mg</title>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin 40mg</title>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 80mg</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26</title>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.73" spread="12.644"/>
                    <measurement group_id="O2" value="-5.46" spread="14.079"/>
                    <measurement group_id="O3" value="-1.78" spread="10.997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in eGFR at Week 52 [LOCF]</title>
        <time_frame>Assessed at Baseline and Week 52 [LOCF]</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 10 mg</title>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin 40 mg</title>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 80 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in eGFR at Week 52 [LOCF]</title>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.70" spread="14.551"/>
                    <measurement group_id="O2" value="-7.29" spread="20.040"/>
                    <measurement group_id="O3" value="-1.61" spread="12.769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Coefficient Urinary Protein/Creatinine Ratio and Total Cholesterol [TC] Indicating the Relationship Between Renal Effects and Lipid Changes</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52 (LOCF).</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Coefficient Urinary Protein/Creatinine Ratio and Total Cholesterol [TC] Indicating the Relationship Between Renal Effects and Lipid Changes</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52 (LOCF).</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03507"/>
                    <measurement group_id="O2" value="0.14258"/>
                    <measurement group_id="O3" value="0.01600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio TC</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>Assessed at 52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio TC</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07019"/>
                    <measurement group_id="O2" value="0.26855"/>
                    <measurement group_id="O3" value="0.12013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Low Density Lipoprotein Cholesterol [LDL-C]</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Low Density Lipoprotein Cholesterol [LDL-C]</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08588"/>
                    <measurement group_id="O2" value="0.18570"/>
                    <measurement group_id="O3" value="-0.02491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04510"/>
                    <measurement group_id="O2" value="0.16280"/>
                    <measurement group_id="O3" value="0.06739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and High Density Lipoprotein Cholesterol [HDL-C]</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and High Density Lipoprotein Cholesterol [HDL-C]</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15614"/>
                    <measurement group_id="O2" value="0.06987"/>
                    <measurement group_id="O3" value="0.14226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and HDL-C</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and HDL-C</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16111"/>
                    <measurement group_id="O2" value="0.26194"/>
                    <measurement group_id="O3" value="0.18918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Non-high Density Lipoprotein Cholesterol [nonHDL-C]</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Non-high Density Lipoprotein Cholesterol [nonHDL-C]</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12068"/>
                    <measurement group_id="O2" value="0.15929"/>
                    <measurement group_id="O3" value="-0.05186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02594"/>
                    <measurement group_id="O2" value="0.24018"/>
                    <measurement group_id="O3" value="0.07381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Triglyceride [TG]</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Triglyceride [TG]</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14569"/>
                    <measurement group_id="O2" value="0.04948"/>
                    <measurement group_id="O3" value="-0.08471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TG</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TG</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05251"/>
                    <measurement group_id="O2" value="0.11755"/>
                    <measurement group_id="O3" value="0.01345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13572"/>
                    <measurement group_id="O2" value="0.07339"/>
                    <measurement group_id="O3" value="-0.08855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05945"/>
                    <measurement group_id="O2" value="0.12132"/>
                    <measurement group_id="O3" value="-0.02666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13689"/>
                    <measurement group_id="O2" value="0.12931"/>
                    <measurement group_id="O3" value="-0.08108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02775"/>
                    <measurement group_id="O2" value="0.06535"/>
                    <measurement group_id="O3" value="-0.01569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16755"/>
                    <measurement group_id="O2" value="0.08891"/>
                    <measurement group_id="O3" value="-0.11221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06085"/>
                    <measurement group_id="O2" value="0.12507"/>
                    <measurement group_id="O3" value="-0.02841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein A-1 [ApoA-1]</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein A-1 [ApoA-1]</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15859"/>
                    <measurement group_id="O2" value="0.13133"/>
                    <measurement group_id="O3" value="0.15516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoA-1</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoA-1</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16587"/>
                    <measurement group_id="O2" value="0.18469"/>
                    <measurement group_id="O3" value="0.18832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein B [ApoB]</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein B [ApoB]</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02276"/>
                    <measurement group_id="O2" value="0.21405"/>
                    <measurement group_id="O3" value="0.04578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05397"/>
                    <measurement group_id="O2" value="0.29486"/>
                    <measurement group_id="O3" value="0.11079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07846"/>
                    <measurement group_id="O2" value="0.13910"/>
                    <measurement group_id="O3" value="-0.02825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio</title>
        <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio</title>
          <description>Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00600"/>
                    <measurement group_id="O2" value="0.22710"/>
                    <measurement group_id="O3" value="0.03684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="297"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00642"/>
                    <measurement group_id="O2" value="0.14331"/>
                    <measurement group_id="O3" value="0.04311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13220"/>
                    <measurement group_id="O2" value="0.35715"/>
                    <measurement group_id="O3" value="0.18971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05514"/>
                    <measurement group_id="O2" value="0.19842"/>
                    <measurement group_id="O3" value="0.00038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10037"/>
                    <measurement group_id="O2" value="0.21205"/>
                    <measurement group_id="O3" value="0.12270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08593"/>
                    <measurement group_id="O2" value="0.00032"/>
                    <measurement group_id="O3" value="0.06930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14758"/>
                    <measurement group_id="O2" value="0.26805"/>
                    <measurement group_id="O3" value="0.17550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06694"/>
                    <measurement group_id="O2" value="0.17296"/>
                    <measurement group_id="O3" value="-0.01144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09189"/>
                    <measurement group_id="O2" value="0.33769"/>
                    <measurement group_id="O3" value="0.14988"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="297"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07271"/>
                    <measurement group_id="O2" value="0.08654"/>
                    <measurement group_id="O3" value="-0.02876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02947"/>
                    <measurement group_id="O2" value="0.27198"/>
                    <measurement group_id="O3" value="0.08787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04785"/>
                    <measurement group_id="O2" value="0.11256"/>
                    <measurement group_id="O3" value="-0.01362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01798"/>
                    <measurement group_id="O2" value="0.20127"/>
                    <measurement group_id="O3" value="0.05369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08211"/>
                    <measurement group_id="O2" value="0.16654"/>
                    <measurement group_id="O3" value="-0.03001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03476"/>
                    <measurement group_id="O2" value="0.10902"/>
                    <measurement group_id="O3" value="0.04508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08468"/>
                    <measurement group_id="O2" value="0.12805"/>
                    <measurement group_id="O3" value="-0.04102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01528"/>
                    <measurement group_id="O2" value="0.21198"/>
                    <measurement group_id="O3" value="0.05251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14207"/>
                    <measurement group_id="O2" value="0.11171"/>
                    <measurement group_id="O3" value="0.13429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16085"/>
                    <measurement group_id="O2" value="0.15933"/>
                    <measurement group_id="O3" value="0.17306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00569"/>
                    <measurement group_id="O2" value="0.20008"/>
                    <measurement group_id="O3" value="0.04833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10997"/>
                    <measurement group_id="O2" value="0.30537"/>
                    <measurement group_id="O3" value="0.15652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05906"/>
                    <measurement group_id="O2" value="0.13706"/>
                    <measurement group_id="O3" value="-0.01775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio</title>
        <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio</title>
          <description>Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04760"/>
                    <measurement group_id="O2" value="0.25636"/>
                    <measurement group_id="O3" value="0.07766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and TC</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and TC</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01586"/>
                    <measurement group_id="O2" value="-0.03124"/>
                    <measurement group_id="O3" value="0.00101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and TC</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and TC</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13489"/>
                    <measurement group_id="O2" value="-0.18105"/>
                    <measurement group_id="O3" value="-0.14690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03010"/>
                    <measurement group_id="O2" value="-0.00944"/>
                    <measurement group_id="O3" value="0.02609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11072"/>
                    <measurement group_id="O2" value="-0.12835"/>
                    <measurement group_id="O3" value="-0.11378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11373"/>
                    <measurement group_id="O2" value="0.01123"/>
                    <measurement group_id="O3" value="0.07576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14457"/>
                    <measurement group_id="O2" value="-0.15546"/>
                    <measurement group_id="O3" value="0.08841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01709"/>
                    <measurement group_id="O2" value="-0.05610"/>
                    <measurement group_id="O3" value="-0.02569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17729"/>
                    <measurement group_id="O2" value="-0.19501"/>
                    <measurement group_id="O3" value="-0.17911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and TG</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and TG</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10533"/>
                    <measurement group_id="O2" value="-0.00604"/>
                    <measurement group_id="O3" value="-0.09437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and TG</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and TG</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24494"/>
                    <measurement group_id="O2" value="-0.07059"/>
                    <measurement group_id="O3" value="-0.15586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05426"/>
                    <measurement group_id="O2" value="-0.01643"/>
                    <measurement group_id="O3" value="-0.04256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26268"/>
                    <measurement group_id="O2" value="-0.08593"/>
                    <measurement group_id="O3" value="-0.23226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01040"/>
                    <measurement group_id="O2" value="0.00241"/>
                    <measurement group_id="O3" value="0.00189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19850"/>
                    <measurement group_id="O2" value="-0.06481"/>
                    <measurement group_id="O3" value="-0.17579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06356"/>
                    <measurement group_id="O2" value="-0.04402"/>
                    <measurement group_id="O3" value="-0.05499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26802"/>
                    <measurement group_id="O2" value="-0.11804"/>
                    <measurement group_id="O3" value="-0.24204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08146"/>
                    <measurement group_id="O2" value="0.05333"/>
                    <measurement group_id="O3" value="0.05845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17909"/>
                    <measurement group_id="O2" value="0.08090"/>
                    <measurement group_id="O3" value="0.12787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01427"/>
                    <measurement group_id="O2" value="0.08821"/>
                    <measurement group_id="O3" value="0.00737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15146"/>
                    <measurement group_id="O2" value="0.04886"/>
                    <measurement group_id="O3" value="-0.12168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04088"/>
                    <measurement group_id="O2" value="0.06598"/>
                    <measurement group_id="O3" value="-0.01652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio</title>
        <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin Treatments pooled</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin Treatment</description>
          </group>
          <group group_id="O3">
            <title>All Treatment</title>
            <description>All Treatments pooled</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio</title>
          <description>Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52</description>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26146"/>
                    <measurement group_id="O2" value="0.05248"/>
                    <measurement group_id="O3" value="-0.22109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rosuvastatin 10mg</title>
        </group>
        <group group_id="E2">
          <title>Rosuvastatin 40mg</title>
        </group>
        <group group_id="E3">
          <title>Atorvastatin 80mg</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Left Ventricular Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Diabetic Eye Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Vitreous Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Diabetic Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Ileus Paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Intestinal Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Soft Tissue Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Abdominal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Abscess Limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Vascular Graft Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastases To Central Nervous System</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Factitious Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Diabetic Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pickwickian Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Sleep Apnoea Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Femoral Arterial Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Poor Peripheral Circulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

